Clinical trials: Advanced Solid Tumors, open to volunteers
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 483 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body…
- Trial name
- NCT04879121
- Testing
- Larotrectinib Sulfate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Advanced Solid Tumors With MTAP Deletion
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors（G-MAP 101）
This is a multicenter, single-arm, open-label, dose-escalation, dose-expansion study to evaluate the safety, tolerability, PK/PD, and preliminary anti-tumor activity of GH56 Capsule in subjects with advanced solid tumors who have…
- Trial name
- NCT06796699
- Testing
- GH56 Capsule
- Where
- 25 sites in China
- Volunteers
- 200 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Advanced / Metastatic Solid Tumors, Advanced Malignancy
Immunotherapy Master Trial for Advanced Cancers
Over the past decade, cancer immunotherapy has profoundly transformed oncology by harnessing the patient's immune system to target tumors.
- Trial name
- METAREM (NCT07431073)
- Testing
- METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each
- Where
- France
- Volunteers
- 275 people
- Sponsor
- UNICANCER
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with…
- Trial name
- NCT05118789
- Testing
- Zidesamtinib (NVL-520)
- Where
- 63 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Nuvalent Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a…
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- TAPUR (NCT02693535)
- Testing
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Where
- 181 sites in United States, Puerto Rico
- Volunteers
- 4,200 people
- Sponsor
- American Society of Clinical Oncology
Advanced Solid Tumor
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the…
- Trial name
- MYTHIC (NCT04855656)
- Testing
- Lunresertib, RP-3500, Debio0123
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 464 people
- Sponsor
- Debiopharm International SA
Advanced Cancer, Advanced Solid Tumor
SLV-154 Treatment of Advanced Cancers
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT06771219
- Testing
- SLV-154
- Where
- 12 sites in United States
- Volunteers
- 250 people
- Sponsor
- Solve Therapeutics
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
This trial investigates the experience and satisfaction of care in patients with cancer that has spread to other places in the body (advanced) and their caregivers living in underserved areas of Kenya, Nigeria, Ghana, South…
- Trial name
- NCT04984551
- Testing
- Extension of Community Health (ECHO) Telementoring Clinic, In-Country Workshops, Professional Oncology Educations Programs
- Where
- United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors, Advanced Solid Tumors Cancer
ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors
This ambispective observational cohort study will evaluate biological changes, palliative outcomes, and safety associated with ET-SPACE whole-body infrared hyperthermia in patients with advanced solid tumors.
- Trial name
- HEAIS-009 (NCT07793214)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhejiang Hospital
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Locally Advanced Solid Tumor
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
- Trial name
- NCT06658353
- Testing
- VC004 Capsules
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Advanced Solid Tumors
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
- Trial name
- NCT05533697
- Testing
- mRNA-4359, Pembrolizumab, Ipilimumab
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 361 people
- Sponsor
- ModernaTX, Inc.
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called TRK fusion cancer.
- Trial name
- NCT04945330
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Bayer
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Special Drug Use-results Surveillance of Tafinlar/Mekinist
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.
- Trial name
- NCT06262919
- Testing
- Tafinlar/Mekinist
- Where
- 70 sites in Japan
- Volunteers
- 110 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer, Metastatic Solid Tumor
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors.
- Trial name
- NCT05004116
- Testing
- Repotrectinib, Irinotecan and temozolomide
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center